Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IQP-AS-118
- Development stage
- Unknown
- Lead developer
- InQpharm
01
Overview
IQP-AS-118 is an investigational product developed by InQpharm Group intended for the management of elevated blood pressure and low-density lipoprotein (LDL) cholesterol. The precise composition, active ingredients, and detailed mechanism of action are not publicly available in the provided sources, but it is being evaluated for its effects on cardiovascular risk factors in individuals with elevated blood pressure and LDL cholesterol. The study focuses on benefit and tolerability, aiming to determine its impact on both blood pressure and lipid metabolism in a clinical (pilot) setting[2].
- Brand names
- IQP-AS-118IQP-AS118IQP-AS 118
- Other names
- IQP-AS-118IQP-AS118IQP-AS 118
Beyond the preview
Go deeper on IQP-AS-118.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IQP-AS-118.